 The objective of the trial is to compare the treatment of patients with advanced gastric cancer without evidence of distant metastases treated with D2 radical gastrectomy and intraperitoneal chemoperfusion HIPEC and postoperative chemotherapy Group B and patients treated with D2 radical gastrectomy alone and postoperative chemotherapy Group A. 